DVA vs UTHR
DaVita vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
70
Buy
| Metric | DVA | UTHR |
|---|
| AI Score |
53
|
70
|
| Price |
$177.63
|
$518.62
|
| P/E Ratio |
15.18×
|
16.97×
|
| ROE |
-114.7%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
31.0%
|
86.1%
|
| Debt / Equity |
-14.09×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
28.1
|
44.3
|
| Beta |
0.87
|
0.564
|
| Expected Upside |
+1.8%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for DVA versus UTHR.
UTHR leads by 17 points.
UTHR scores 70/100 (Buy) versus DVA at 53/100 (Watch).
DVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 3 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — high leverage (debt-to-equity 77.99) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 13.6 is inexpensive for the broad market — Value
- ROE of 181.2% shows genuine earnings power backing the valuation — Value
- 3 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 101.2x prices in significant intangible value — Value
- Debt-to-equity of 77.99 adds balance-sheet risk to the value case — Value
- RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
UTHR Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 10.6% downside vs 1.2% upside.